Shionogi & Co.

Money Moves

As of October 2026: Acquiring IntraBio through its U.S. subsidiary

Shionogi agreed to pay $2 billion for IntraBio, a Texas biotech whose single marketed drug treats two inherited neurological disorders. The deal, announced October 5, hands the Osaka-based drugmaker a product that weeks earlier became the first approved treatment for ataxia-telangiectasia, a rare and fatal genetic disease.

Updated Oct 9

New Capabilities

As of July 2026: Maker and marketer of ensitrelvir (XOCOVA)

For years, the only move after a close COVID-19 exposure was to wait and watch for symptoms. Now there is a pill for that.

Updated Jul 29